Wendell Wierenga
Known title: DirectorCIK: 0001239956
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Dermata Reports Positive Results from Tome Cosmetic Study. Dermata Therapeutics said its Tome Foundational Treatment showed positive topline results in a cosmetic study. The study reported that more than 71% of patients had overall skin improvements at day 29. The company’s shares were active with a volume spike during the session. The stock sits near its 52‑week low and an RSI of 34.5.
Transaction History
| CYTK | ▲ Buy | Grant | 75 | $6K | 7/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 2,851 | $0 | 5/27/2026 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 4,032 | $50K | 5/5/2026 | View on chart |
| CYTK | ▼ Sell | Open Market | 4,032 | $302K | 5/5/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 95 | $6K | 4/15/2026 | View on chart |
| CYTK | ▲ Buy | Grant | 98 | $6K | 1/15/2026 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 20,000 | $152K | 12/22/2025 | View on chart |
| CYTK | ▼ Sell | Open Market | 20,000 | $1.3M | 12/22/2025 | View on chart |
| CYTK | ▼ Sell | Open Market | 4,375 | $257K | 10/27/2025 | View on chart |
| CYTK | ▲ Buy | Option Exercise | 4,375 | $44K | 10/27/2025 | View on chart |
| CYTK | ▲ Buy | Grant | 99 | $6K | 10/15/2025 | View on chart |
| DRMA | ▲ Buy | Grant | 20,654 | $0 | 10/6/2022 | View on chart |
| DRMA | ▲ Buy | Grant | 18,110 | $0 | 7/7/2022 | View on chart |
| DRMA | ▲ Buy | Grant | 10,593 | $0 | 4/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cytokinetics Launches ASPEN-HCM Real-World Study
Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.
Cytokinetics Launches ASPEN-HCM Real-World Study. Cytokinetics has initiated the ASPEN-HCM study to evaluate MYQORZO in real-world patients with symptomatic obstructive hypertrophic cardiomyopathy. The company also announced four upcoming presentations at the HFSA Annual Scientific Meeting 2026. These clinical updates provide new data points for investors, while the stock currently trades near its 52-week low.